MISSISSAUGA, ON, Oct. 14, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") has received a favourable award from an extensive and comprehensive arbitration proceeding, related to a contractual dispute with Sun Pharmaceuticals Industries, Inc. ("Sun") regarding Sun's breach of certain provisions of its supply and distribution agreement with the Company (the "Agreement"). The contractual dispute involved Sun's launch of Absorica LD® in Canada and Sun's claim of ownership of certain clinical data. The arbitration process, as outlined in the Agreement, was mutually agreed upon by both Cipher and Sun from the outset as a binding method of dispute resolution. The arbitrator's award included a declaration that Cipher is the rightful owner of the clinical data in dispute. The arbitrator further determined that Sun breached the Agreement by submitting Cipher's clinical data to Health Canada to obtain approval for Absorica LD®.
Read more at newswire.ca
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Cipher Pharmaceuticals Receives Successful Arbitration Award
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
